• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Cabozantinib is associated with an intracranial response in the treatment of brain metastases from renal cell carcinoma

byJamie ParkandSze Wah Samuel Chan
October 25, 2021
in Neurology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Intracranial response rate of 55% was reported in patients receiving cabozantinib with progressing brain metastases with no concomitant brain-directed local therapy

2. Cabozantinib was well-tolerated with common adverse events such as fatigue, diarrhea and palmar-plantar erythrodysesthesia

Evidence Rating Level: 2 (Good)

Study Rundown: Patients with metastatic renal cell carcinoma (RCC) may develop brain metastases, increasing their morbidity and mortality. Currently, the standard treatment of care includes local therapies targeting metastases (e.g., stereotactic radiosurgery, whole-brain radiotherapy). RCC patients with brain metastases were poorly represented in other clinical trials and the aim of this study was to characterize cabozantinib monotherapy in the treatment of progressive brain metastases. This study aimed to evaluate the efficacy and safety of cabozantinib for the treatment of brain metastases in patients with metastatic RCC. Patients were divided into two cohorts. Cohort A comprised of patients with progressing brain metastases who did not receive brain-directed local therapy concomitantly. Cohort B comprised of patients with stable brain metastases who received brain-directed local therapy concomitantly. Cabozantinib showed a notable intracranial response rate of 55% and 47% in cohorts A and B, respectively. Commonly reported adverse events included fatigue, diarrhea and palmar-plantar erythrodysesthesia. Limitations to the study include having a low number of patients in each cohort and the lack of information regarding other concomitant medications that the patients may be on, which could influence the safety profile of cabozantinib. Overall, this study demonstrated that cabozantinib could be an effective treatment for patients with brain metastases from RCC, particularly patients with progressive brain metastases. However, further investigation is required to confirm the findings and establish a more comprehensive efficacy and safety profile of cabozantinib in patients with brain metastases, including in combination with other therapies.

Click to read the study in JAMA Oncology

Relevant Reading: Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population

In-Depth [retrospective cohort]: This was a multicenter, international, retrospective cohort study of 88 patients at 15 academic centers in the United States, Belgium, France, and Spain. Patients were eligible if they had brain metastases from RCC and received cabozantinib between January 2014 and October 2020. The patients were divided into 2 cohorts. Cohort A included patients with progressing brain metastases at the start of cabozantinib who were not receiving concomitant brain-directed local therapy. Cohort B included patients with stable brain metastases at the start of cabozantinib who were receiving brain-directed local therapy concomitantly. The study examined the intracranial and extracranial objective response rates (ORRs) as well as the safety profile of cabozantinib. The intracranial ORR for Cohort A and B were 55% (95% confidence interval [CI]: 36%-73%) and 47% (95% CI: 33%-61%), respectively. 32% of the patients in Cohort A experienced stable disease compared to 42% of patients in Cohort B. 13% of the patients in Cohort A and 11% of patients in Cohort B experienced progressive disease. The extracranial ORR for Cohort A and B were 48% (95% CI: 31%-66%) and 38% (95% CI: 25%-52%), respectively. The median overall survival was 16.0 months (95%CI, 12.0-21.9months). Commonly reported adverse events included fatigue (77%), diarrhea (46%) and palmar-plantar erythrodysesthesia (32%). There were no reported deaths and neurological toxic effects (e.g., seizure, brain hemorrhage, stroke).

RELATED REPORTS

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

Telaglenastat addition to cabozantinib did not demonstrate benefit in pre-treated advanced renal cell carcinoma

Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: brain metastatescabozantinibrenal cell neoplasm
Previous Post

Nivolumab is a potential treatment option for patients with relapsing malignant mesothelioma

Next Post

Comparing incidence and severity of COVID-19 between statin users and non-users

RelatedReports

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma

October 11, 2022
Pediatric renal and thyroid cancer rates increase
Oncology

Telaglenastat addition to cabozantinib did not demonstrate benefit in pre-treated advanced renal cell carcinoma

September 12, 2022
Oncology

Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma

April 25, 2022
#VisualAbstract: Polypill plus aspirin treatment decreases cardiovascular event incidence
StudyGraphics

#VisualAbstract: Lenvatinib plus pembrolizumab improves overall survival and progression free survival for advanced renal cell carcinoma treatment

April 20, 2021
Next Post
Computed tomography improves diagnostic certainty in the emergency department

Comparing incidence and severity of COVID-19 between statin users and non-users

Factors contributing to parents providing alcohol sips to adolescents

Electronic Health Record data may be able to predict likelihood of Alcohol Withdrawal Syndrome among veterans

Adalimumab aids in control of noninfectious uveitis

Corticosteroid use may not offer benefit for children with acute orbital cellulitis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options